SUNSHINE BIOPHARMA INC (SBFM) Stock Fundamental Analysis
USA - NASDAQ:SBFM - US8677817004 - Common Stock
1.4 USD
-0.09 (-6.04%)
Taking everything into account, SBFM scores 4 out of 10 in our fundamental rating. SBFM was compared to 533 industry peers in the Biotechnology industry. SBFM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SBFM is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year SBFM has reported negative net income.
In the past year SBFM has reported a negative cash flow from operations.
In the past 5 years SBFM always reported negative net income.
In the past 5 years SBFM always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -19.73%, SBFM is in the better half of the industry, outperforming 76.55% of the companies in the same industry.
SBFM has a better Return On Equity (-24.55%) than 80.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| ROIC | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 33.33%, SBFM is in the better half of the industry, outperforming 73.55% of the companies in the same industry.
SBFM's Gross Margin has declined in the last couple of years.
SBFM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
2. Health
2.1 Basic Checks
SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SBFM has been increased compared to 1 year ago.
Compared to 5 years ago, SBFM has more shares outstanding
SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.09, we must say that SBFM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SBFM (-1.09) is comparable to the rest of the industry.
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.09 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
A Current Ratio of 5.00 indicates that SBFM has no problem at all paying its short term obligations.
SBFM has a Current ratio of 5.00. This is comparable to the rest of the industry: SBFM outperforms 55.91% of its industry peers.
A Quick Ratio of 2.66 indicates that SBFM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.66, SBFM is not doing good in the industry: 65.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
SBFM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.92%, which is quite impressive.
The Revenue has grown by 19.22% in the past year. This is quite good.
The Revenue has been growing by 340.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)85.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.08%
Revenue 1Y (TTM)19.22%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%1.15%
3.2 Future
Based on estimates for the next years, SBFM will show a very strong growth in Earnings Per Share. The EPS will grow by 41.65% on average per year.
Based on estimates for the next years, SBFM will show a very strong growth in Revenue. The Revenue will grow by 26.02% on average per year.
EPS Next Y98.37%
EPS Next 2Y41.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.61%
Revenue Next 2Y26.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SBFM. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 4.16, the valuation of SBFM can be described as very cheap.
SBFM's Price/Forward Earnings ratio is rather cheap when compared to the industry. SBFM is cheaper than 98.87% of the companies in the same industry.
SBFM is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.39, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.16 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SBFM's earnings are expected to grow with 41.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.65%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SBFM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SBFM (11/19/2025, 2:54:51 PM)
1.4
-0.09 (-6.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.85%
Inst Owner Change25.57%
Ins Owners0.05%
Ins Owner Change0%
Market Cap6.38M
Revenue(TTM)36.34M
Net Income(TTM)-6.31M
Analysts82.86
Price Target7.14 (410%)
Short Float %20.89%
Short Ratio0.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-44.44%
EPS NQ rev (3m)-44.44%
EPS NY rev (1m)-45.61%
EPS NY rev (3m)-45.61%
Revenue NQ rev (1m)-8.26%
Revenue NQ rev (3m)-8.26%
Revenue NY rev (1m)-8.39%
Revenue NY rev (3m)-8.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.16 | ||
| P/S | 0.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.25 | ||
| P/tB | 0.28 | ||
| EV/EBITDA | N/A |
EPS(TTM)-51.88
EYN/A
EPS(NY)0.34
Fwd EY24.04%
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS7.97
BVpS5.63
TBVpS5.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.33% | ||
| FCFM | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
F-Score4
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 549.76% | ||
| Cap/Sales | 4.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5 | ||
| Quick Ratio | 2.66 | ||
| Altman-Z | -1.09 |
F-Score4
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)874.71%
Cap/Depr(5y)526.53%
Cap/Sales(3y)5.32%
Cap/Sales(5y)3.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.08%
EPS Next Y98.37%
EPS Next 2Y41.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.22%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%1.15%
Revenue Next Year9.61%
Revenue Next 2Y26.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.81%
OCF growth 3YN/A
OCF growth 5YN/A
SUNSHINE BIOPHARMA INC / SBFM FAQ
Can you provide the ChartMill fundamental rating for SUNSHINE BIOPHARMA INC?
ChartMill assigns a fundamental rating of 4 / 10 to SBFM.
What is the valuation status for SBFM stock?
ChartMill assigns a valuation rating of 4 / 10 to SUNSHINE BIOPHARMA INC (SBFM). This can be considered as Fairly Valued.
How profitable is SUNSHINE BIOPHARMA INC (SBFM) stock?
SUNSHINE BIOPHARMA INC (SBFM) has a profitability rating of 2 / 10.
What is the financial health of SUNSHINE BIOPHARMA INC (SBFM) stock?
The financial health rating of SUNSHINE BIOPHARMA INC (SBFM) is 6 / 10.
Can you provide the expected EPS growth for SBFM stock?
The Earnings per Share (EPS) of SUNSHINE BIOPHARMA INC (SBFM) is expected to grow by 98.37% in the next year.